The Cancer Methylome:
The Cancer Methylome Project aims to build a comprehensive
profile of the human cancer methylome. The focus of this project is to provide a better understanding of how
aberrant methylation affects the aetiology of cancer, and how we can use this information to identify novel
diagnostic and prognostic markers or new therapeutic targets.
|
The Epigenomics of Common Disease:
Epigenetic factors, such as DNA methylation, are well established in the evolution
of human cancer genomes; however the possible role they may play in other common diseases has not yet been elucidated. Epigenomics
may add an extra dimension, upon identified susceptibility S.N.P.s & C.N.V.s, in the interplay between the environment and the genome
in common diseases, and further aid in the understanding of the pathogenesis of these disorders.
|
High-throughput
DNA methylation pipeline:
Methylated DNA immunoprecipitation (MeDIP) is a comprehensive but cumbrous technique
to assess genome-wide DNA methylation profiles. This project aims to increase the throughput of the assay as part of an integrated
analysis pipeline to ultimately aid the discovery of novel biomarkers for use in disease diagnostics and drug development.
|
BatCave:
BatCave
is an integrated database designed for the storage
and visualisation of data generated by the 'Batman'
(Bayesian Tool for Methylation Analysis) analysis
tool. The BatCave facilitates the
integration of our work with publicly available
datasets via the DAS (Distributed Annotation
System) communication protocol.
|
ZooArray: Epigenetic Insights into Vertebrate Genomes:
Epigenetic modifications such as DNA methylation and post-translational modifications of histones
play crucial roles in organizing chromatin structure, specifically at the non-coding regulatory regions which facilitates gene expression
and regulates other cellular processes. The aim of this project is to elucidate the epigenetic states of the evolutionarily conserved
genomic sequences in order to understand the importance of these modifications during vertebrate evolution.
|
NET
BioBank:
Neuroendocrine Tumors (NETs) are a heterogeneous group of neoplasms which
arise from the hormone-producing cells of the body’s nervous and endocrine systems. NETs affect 1/50 000 of the UK population.
The project aims to carry out an integrated (epi)genomic analysis of the NET BioBank established at the Royal Free and UCL
Hospitals to identify new biomarkers for translation into diagnostics and therapeutics
|
Statistical Cancer Genomics:
We develop advanced statistical methodology to enable a more meaningful interpretation of large
scale multi-dimensional cancer genomic data. Specifically, we are applying tools from network theory, Bayesian statistics and machine learning
to help address a variety of challenges in medical genomics and epigenomics, such as the characterisation of aberrant signalling pathway
patterns in cancer, identification of cancer gene networks or the elucidation of the regulatory networks governing cancer stem cells.
|
Inflammatory Bowel Disease:
Inflammation is a key mechanism for maintaining immunological
integrity. We aim to identify epigenetic factors contributing
to Inflammatory Bowel Disease (IBD) by performing genome-wide
screens in samples from IBD discordant monozygotic twins.
|
HEROIC:
The HEROIC Project provides a resource for functional
studies into chromatin remodeling, mouse embryonic
stem (ES) cell differentiation and regulation
of the (epi)genome in general.
|
Human
Epigenome Project:
Provides an epigenetic resource
of genome-wide DNA methylation reference profiles
in human tissues and cell lines.
|
The
MHC Haplotype Project:
The
MHC Haplotype Project provides genetic
resources for association studies into inflammatory,
autoimmune and infectious disease as well
as
forming a framework for population genetic
studies.
|
The
LRC Haplotype Project:
The
LRC Haplotype Project provides genetic
resources for association studies into inflammatory,
autoimmune and infectious disease as well
as
forming a framework for population genetic
studies.
|
contact@cancer.ucl.ac.uk
+44 (0)20 7679 6500
